Graeme Sloan – Managing Director – Kali Metals (ASX:KM1) is a portfolio of assets that represents one of the largest and most prospective exploration packages across Australia’s world leading hard-rock lithium fields.
Copyright 2024 – Finance News Network
Source: Finance News Network
06 Aug 2020 - Centuria Industrial REIT (ASX:CIP) Fund Manager, Jesse Curtis talks full year 2020 results, portfolio metrics and guidance.
Read More05 Oct 2022 - Etherstack Limited (ASX:ESK) CEO and Executive Director David Deacon discusses recent agreements with Samsung and Nokia and the outlook for the months ahead.
Read More06 Sep 2021 - Paragon Care Limited (ASX:PGC) CEO Phil Nicholl provides an update on FY21 results, which reported growth in all key financial metrics and the recommencement of dividends.
Read More18 May 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's pipeline and discusses the recent licensing of an asset from UCLA.
Read More2 Dec 2019 - DomaCom Limited (ASX:DCL) CEO Arthur Naoumidis talks about a year of significant progress with regulators, the company's capital raising to accelerate marketing and FUM and the tailwinds making fractional investment attractive.
Read More23 Feb 2024 - Discover Sunshine Metals' strategic focus on Queensland's prolific gold and base metal districts, unveiling promising exploration ventures and recent resource upgrades.
Read More19 Mar 2024 - Torque Metals Limited (ASX:TOR) Managing Director Cristian Moreno discusses the roadmap for the company and promising recent results.
Read More13 May 2020 - Elixinol Global (ASX:EXL) CEO, Oliver Horn talks about its strategy to create a global nutraceuticals brand, with a focus on higher margin, consumer branded products, new management team, capital raising and FY 20 outlook.
Read More22 Nov 2022 - Radiopharmaceutical Theranostics Limited (ASX:RAD) Managing Director and CEO Riccardo Canevari discusses the progress of the company's brain, lung and prostate cancer therapies.
Read More19 Aug 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.
Read More
